Application of therapeutic physical factors in the therapy of psoriatic onychodystrophy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: One of the common clinical manifestations of psoriasis is nail plate damage, leading to psoriatic onychodystrophy (PОD). PОD is often accompanied by severe pain syndrome, causing difficulties in wearing shoes or socks and performing daily household tasks, which leads to a decrease in quality of life and contributes to the development of anxiety and depression. Studies on PОD treatment have demonstrated the effectiveness of non-pharmacological approaches, particularly pulsed dye laser (PDL) therapy and medium-frequency pulsed currents (Darsonval therapy), which promote regression of clinical symptoms.

Aim: To assess the clinical efficacy of a comprehensive treatment approach incorporating PDL and Darsonval therapy in patients with psoriatic onychodystrophy.

Materials and methods: A prospective, controlled, randomized study was conducted, including 110 patients with PОD, who were randomly assigned to four groups using simple fixed randomization. Group 1 (Control, n=27): received only basic therapy (BT) consisting of topical application of calcipotriol ointment. Group 2 (Comparison Group 1, n=28): received three courses of Darsonval therapy in addition to BT Group 3 (Comparison Group 2, n=28): received 5–6 sessions of PDL therapy, performed at one-month intervals, in addition to BT. Group 4 (Main Study Group, n=27): received both Darsonval therapy and PDL therapy in combination with BT. The clinical assessment included the frequency of nail matrix and nail bed lesions, as well as the Nail Psoriasis Severity Index (NAPSI) and the Dermatology Life Quality Index (DLQI)scores.

Results: NAPSI assessment revealed widespread involvement of the nail bed and matrix among patients. The initial DLQI score was 23.6 points, indicating a significant negative impact of nail disease on patients’ daily lives. All treatment groups demonstrated clinical improvement, but the extent of symptom regression depended on the treatment regimen. Additional therapeutic physical factors further enhanced effectiveness, with the combined use of Darsonval therapy and PDL therapy producing the best clinical outcomes.

Conclusion: Incorporating physical therapy modalities into the standard treatment regimen for psoriatic onychodystrophy significantly improves clinical effectiveness. The combined application of pulsed dye laser and Darsonval therapy achieves the greatest regression of clinical manifestations and substantial improvements in patients’ quality of life.

Full Text

Restricted Access

About the authors

Alesya Yu. Blokina-Mechtalina

Mechtalina Clinic

Author for correspondence.
Email: alesya_mechtalina@mail.ru
ORCID iD: 0009-0002-3223-8622
Russian Federation, Zhukovsky

Natalia B. Korchazhkina

Central State Medical Academy

Email: n9857678103@gmail.com
ORCID iD: 0000-0001-6913-8778
SPIN-code: 9733-7646

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Sergey N. Nagornev

Central State Medical Academy

Email: drnag@mail.ru
ORCID iD: 0000-0002-1190-1440
SPIN-code: 2099-3854

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. All-Russian public organization “Russian society of dermatovenerologists and cosmetologists”. Clinical guidelines. Psoriasis. M., 2023. 78 p. (In Russ.)
  2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6
  3. Canal-García E, Bosch-Amate X, Belinchón I, Puig L. Nail Psoriasis. Actas Dermo-Sifiliográficas. 2022;113(5):481-490. English, Spanish. doi: 10.1016/j.ad.2022.01.006
  4. Kaeley GS, Eder L, Aydin SZ, et al. Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs. Journal of Rheumatology. 2021;48(8):1208-1220. doi: 10.3899/jrheum.201471
  5. Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131-135. doi: 10.5114/reum.2017.68912
  6. Reich K. Approach to managing patients with nail psoriasis. Journal of the European Academy of Dermatology and Venereology. 2009;23 Suppl 1:15-21. doi: 10.1111/j.1468-3083.2009.03364.x
  7. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail Psoriasis, the unknown burden of disease. Journal of the European Academy of Dermatology and Venereology. 2014;28(12):1690-5. doi: 10.1111/jdv.12368
  8. Alavi MAM. Psoriatic onychodystrophy. Bulletin of Postgraduate Medical Education. 2022;1:38–50.
  9. Gisondi P, Gracia-Cazaña T, Kurzen H, Galván J. Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids. Journal of Clinical Medicine. 2024;13(15):4484. doi: 10.3390/jcm13154484
  10. Fineshina YeI. PUVA-vanny v vosstanovitel’nom lechenii psoriaticheskoy onikhodistrofii [dissertation]. Moscow; 2010. Available from: https://www.dissercat.com/content/puva-vanny-v-vosstanovitelnom-lechenii-psoriaticheskoi-onikhodistrofii?ysclid=m4mm4q3ilz 411068300.
  11. Peruzzo J, Garbin GC, Maldonado G, Cestari TF. Nail psoriasis treated with pulsed dye laser. Anais Brasileiros de Dermatologia. 2017;92(6):885-887. doi: 10.1590/abd1806-4841.20175918
  12. Al-Mutairi N, Noor T, Al-Haddad A. Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis. Dermatology and Therapy. 2014;4(2):197-205. doi: 10.1007/s13555-014-0057-y
  13. Bovenschen HJ, Erceg A, Van Vlijmen-Willems I, et al. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization. Journal of Dermatological Treatment. 2007;18(1):32-9. doi: 10.1080/09546630601028760
  14. Liu A, Moy RL, Ross EV, et al. Pulsed dye laser and pulsed dye laser-mediated photodynamic therapy in the treatment of dermatologic disorders. Dermatologic Surgery. 2012;38(3):351-66. doi: 10.1111/j.1524-4725.2011.02293.x
  15. Alavi MAM, Monaenkova MK, Molochkov AV, et al. Use of PUVA therapy in combination with darsonvalization in the treatment of psoriatic onychodystrophy. Biomedical Photonics. 2023;12(S4):49–50.
  16. Kulikova NG, Alavi MAM. Darsonvalization method in combination with PUVA therapy in the treatment of patients with psoriatic onychodystrophy. Resort Medicine. 2023;1:69–73. doi: 10.51871/2304-0343_2023_1_69
  17. Zou Q, Luo Y, Hao D, et al. Validation and application of the Dermatology Life Quality Index score, a modification of the DLQI score, in psoriasis patients. Journal of Health, Population and Nutrition. 2024;43(1):92. doi: 10.1186/s41043-024-00587-3
  18. Kusuba N, Kitoh A, Dainichi T, et al. Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue. Journal of Allergy and Clinical Immunology. 2018;141(3):972–981.e10. doi: 10.1016/j.jaci.2017.07.033
  19. Segaert S, Ropke M. The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis. Journal of Drugs in Dermatology. 2013;12(8):e129–37.
  20. Mori H, Arita K, Yamaguchi T, et al. Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice. Kobe Journal of Medical Sciences. 2016;62(4):E79–E88
  21. Germán B, Wei R, Hener P, et al. Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis. JCI Insight. 2019;4(2):e123390. doi: 10.1172/jci.insight.123390
  22. Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(15):3387. doi: 10.3390/nu15153387
  23. Karakawa M, Kishimoto M, Ohtsuki M, Komine M. Calcipotriol induces the production of CTACK/CCL27, one of the potential suppressive factors in psoriasis inflammation. Journal of Dermatology. 2021;48(12):1949-1950. doi: 10.1111/1346-8138.16152
  24. Zhang J, Fang H, Wang R, et al. Effect of Calcipotriol on IFN-γ-Induced Keratin 17 Expression in Immortalized Human Epidermal Keratinocyte Cells. Medical Science Monitor. 2017;23:6049–6056. doi: 10.12659/msm.904850
  25. Körver JE, Vissers WH, van Rens DW, et al. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. British Journal of Dermatology. 2007;156(1):130–7. doi: 10.1111/j.1365-2133.2006.07561.x
  26. Tiberio R, Bozzo C, Pertusi G, et al. Calcipotriol induces apoptosis in psoriatic keratinocytes. Clinical and Experimental Dermatology. 2009;34(8):e972-4. doi: 10.1111/j.1365-2230.2009.03518.x
  27. Franssen ME, de Jongh GJ, van Erp PE, van de Kerkhof PC. A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations. Acta Dermato-Venereologica. 2004;84(3):195-200. doi: 10.1080/00015550410025930
  28. Thatai P, Khan AB. Management of nail psoriasis by topical drug delivery: a pharmaceutical perspective. International Journal of Dermatology. 2020;59(8):915–925. doi: 10.1111/ijd.14840
  29. Saner MV, Kulkarni AD, Pardeshi CV. Insights into drug delivery across the nail plate barrier. Journal of Drug Targeting. 2014;22(9):769–89. doi: 10.3109/1061186X.2014.929138
  30. Haghsay Khashechi E, Afaghmehr A, Heydari N, et al. Laser-mediated Solutions: Breaking Barriers in Transdermal Drug Delivery. AAPS PharmSciTech. 2024;25(6):142. doi: 10.1208/s12249-024-02849-z
  31. Wenande E, Anderson RR, Haedersdal M. Fundamentals of fractional laser-assisted drug delivery: An in-depth guide to experimental methodology and data interpretation. Advanced Drug Delivery Reviews. 2020;153:169–184. doi: 10.1016/j.addr.2019.10.003
  32. Rácz E, de Leeuw J, Baerveldt EM, et al. Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. Lasers in Surgery and Medicine. 2010;42(3):201–10. doi: 10.1002/lsm.20898
  33. Kuo YR, Wu WS, Jeng SF, et al. Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers in Surgery and Medicine. 2005;36(1):38–42. doi: 10.1002/lsm.20104
  34. Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. Journal of the European Academy of Dermatology and Venereology. 2009;23(8):891–5. doi: 10.1111/j.1468-3083.2009.03196.x
  35. Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. Lasers in Medical Science. 2018;33(1):173–180. doi: 10.1007/s10103-017-2360-1
  36. Battista T, Scalvenzi M, Martora F, et al. Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clinical, Cosmetic and Investigational Dermatology. 2023;16:1899–1932. doi: 10.2147/CCID.S417679
  37. Taganov AV, Molochkov AV, Kulikova NG, et al. Psoriatic onychodystrophy: Clinical course, diagnosis and therapeutic aspects. Russian Journal of Skin and Venereal Diseases. 2023;26(6):575–596. (In Russ). doi: 10.17816/dv570289
  38. Alavi MAM, Monaenkova MK, Molochkov AV, et al. PUVA therapy and high-frequency pulsed sinusoidal current of high voltage and low power in the treatment of patients with psoriatic onychodystrophy. Biomedical Photonics. 2023;12(S4):12–13.
  39. Nemchaninova OB, Lykova SG, Pozdnyakova ON, et al. The clinical effectiveness of the application of interferential currents for the combined treatment of onychopathies associated with psoriasis and eczema. Problems of Balneology, Physiotherapy and Exercise Therapy. 2016;93(3):4245. (In Russ.). doi: 10.17116/kurort2016342-45
  40. Starodubtseva NL. Izucheniye roli IL-17 v patogeneze psoriaticheskogo protsessa [dissertation]. Moscow; 2011. Available from: https://www.dissercat.com/content/izuchenie-roli-il-17-v-patogeneze-psoriaticheskogo-protsessa?ysclid=m4modnt0vc925434122.
  41. Benkov AA, Nagornev SN, Frolkov VK, Puzyreva GA. Efficiency of combined use of physiotherapeutic factors on the model of microcirculatory-tissue systems. Systems analysis and control in biomedical systems. 2021;2:8–17. doi: 10.36622/VSTU.2021.20.2.001
  42. Ulashchik VS. Combined physical therapy: general information, interaction between physical factors. Problems of Balneology, Physiotherapy and Exercise Therapy. 2016;93(6):411. doi: 10.17116/kurort201664-11
  43. Benkov AA, Nagornev SN, Frolkov VK, et al. Analysis of the mechanisms of synergistic effects in the combined use of physiotherapeutic factors. Physiotherapist. 2021;6:77–87. doi: 10.33920/med-14-2112-08

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86508 от 11.12.2023. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021 г.